RT Journal Article
T1 From Green Technology to Functional Olive Oils: Assessing the Best Combination of Olive Tree-Related Extracts with Complementary Bioactivities.
A1 Hernáez, Álvaro
A1 Jaramillo, Sara
A1 García-Borrego, Aránzazu
A1 Espejo-Calvo, Juan Antonio
A1 Covas, María-Isabel
A1 Blanchart, Gemma
A1 de la Torre, Rafael
A1 Carrasco-Pancorbo, Alegría
A1 Mesa, María Dolores
A1 Fernández-Prior, Maria África
A1 Castañer, Olga
A1 Fitó, Montserrat
K1 3,4-dihydroxyphenylglycol
K1 bioactivity
K1 functional olive oil
K1 hydroxytyrosol
K1 oleocanthal
K1 oleuropein
K1 olive tree
K1 phenolic compound
K1 triterpenes
AB Our aim was to assess the combination of olive tree-related extracts with the most favorable profile of in vitro bioactive properties. We tested the antioxidant (increment of low-density lipoprotein resistance against oxidation), vasoactive (promotion of nitric oxide release and decrease of endothelin-1 production in human umbilical vein endothelial cells), anti-inflammatory (decrease of the endothelial production of vascular cell adhesion molecule-1), and antithrombotic (reduction of the endothelial release of plasminogen activator inhibitor-1) capacities of six phenolic extracts and three triterpenic acid solutions (Ps and Ts, respectively). We tested extracts alone and in combination, at nutritional (Ps: 0.05-0.5 μmol/L; Ts: 0.001-0.1 μmol/L) and nutraceutical doses (Ps: 1-10 μmol/L; Ts: 0.25-10 μmol/L). The combination of Ps rich in 3,4-dihydroxyphenylglycol (76%, P2), hydroxytyrosol (95%, P3), and oleuropein (70%, P4) (final nutritional concentration: 0.15 μmol/L; final nutraceutical concentration: 3 μmol/L) was the best in order to prepare functional products and nutraceuticals with cardioprotective properties, despite the fact that the isolated extract with the greatest in vitro properties was P5 (75% oleocanthal), suggesting a potential synergistic effect among different olive components.
SN 2076-3921
YR 2021
FD 2021-01-30
LK https://hdl.handle.net/10668/28075
UL https://hdl.handle.net/10668/28075
LA en
DS RISalud
RD Apr 11, 2025